Table 2 Univariate and multivariate analyses of clinicopathological factors for failure-free survival

Age

≥65 years vs <65 years†

Initial PSA

≥20 ng/mL vs <20 ng/mL

Pathological T stage

≥T3 vs ≤ T2

Pathological GS

≥8 vs ≤7

Gleason pattern 5

Yes vs no

4.166 (1.351 to 12.76)

0.0133*

Extraprostatic extension

Yes vs no

Lymphovascular invasion

Yes vs no

1.005 (0.323 to 3.130)

0.9935

Positive surgical margin

Yes vs no

Seminal vesicle invasion

Yes vs no

Perineural invasion

Yes vs no

5.876 (1.139 to 107.5)

0.0316*

Timing of SRT

ueSRT vs eSRT vs dSRT

–

–‡

ueSRT + eSRT vs dSRT

3.117 (1.141 to 7.880)

0.0280*

ueSRT vs eSRT + dSRT

SRT technique

3DCRT vs IMRT

Total dose

≥66 Gy vs <66 Gy

Concomitant ADT

Yes vs no

PSA doubling time

≥6 months vs <6 months

–

–‡